baber/WOPTO huggingface dataset:
Patent NZ-237181-A (NZ)
Title: 4-(di-n-propyl)amino-6-aminocarbonyl-1,3,4,5-tetrahydrobenz(cd)indole hippurate and pharmaceutical composition
Inventor: KRESS THOMAS JOSEPH
IPC: A61K31/40
Filed: 1991-02-21
Abstract: 4-(Di-n-propyl)amino-6-aminocarbonyl-1,3,4,5-tetrahydrobenz[cd]indole hippurate and its method of preparation and use are provided.
Patent NZ-237989-A (NZ)
Title: Collapsible kite.
Inventor: HENDERSON ANTHONY ALAN
IPC: A63H27/08
Filed: 1991-09-30
Abstract: PCT No. PCT/GB92/01795 Sec. 371 Date May 31, 1994 Sec. 102(e) Date May 31, 1994 PCT Filed Sep. 30, 1992 PCT Pub. No. WO93/06905 PCT Pub. Date Apr. 15, 1993.A collapsible and foldable kite including frame members, a keel member, spreader supports and a sail. The frame members being fixed to the sail with the aa keel member and spreader supports either fixed to the sail and/or frame members, to brace the sail while flying. At least one of the frame members being hinged to allow the frame members and sail to be folded or rolled into a small package.
Patent NZ-239083-A (NZ)
Title: Endo-xylanase-containing silage composition
Inventor: HARDER ABRAHAM
IPC: A23K30/18
Filed: 1991-07-23
Abstract: Methods and expression constructs are provided for the cloning of genes from fungal origin which encode polypeptides having xylanase activity and their overexpression in a selected microbial host cell. Xylanases of fungal origin generally have lower pH optima and remain stable over a broader pH range than do xylanases of bacterial origin. The present invention provides for the high level production of fungal xylanases which are may be used in a variety of industrial applications requiring xylanase activity at a low pH.
Patent NZ-260241-A (NZ)
Title: Display system enclosure comprises a modular structure comprising a panel frame hinged to a main frame using a bead in a semi-cylindrical groove
Inventor: TEO KIM HUAT
IPC: G09F15/00
Filed: 1994-03-31
Abstract: A hingeless assembly for a protective enclosure is incorporated as part of a modular display system. The protective enclosure (10) features a main frame (11) and an open face panel frame (22). While the main frame (11) and the open face panel frame (22) are assembled from standardized extrusions and joints (20), an elongated cylindrical bead (13) along one of the external edges of the main frame (11) and a semi-cylindrical elongated groove (25) along a corresponding edge of the open face panel frame (22) are slidably fitted over one another to form a modular enclosure. A gasket is disposed along the hingeless assembly to weather-proof the enclosure (10). The hingeless assembly of the enclosure (10) not only allows the open face panel to be opened for easy access, but also seals the interior of the display system from the elements when the open face panel is closed. <IMAGE>
Patent NZ-265896-A (NZ)
Title: Cell phone type mobile funds transaction device
Inventor: ELBAUM HECTOR DANIEL
IPC: G06Q20/32
Filed: 1994-05-13
Abstract: PCT No. PCT/AU94/00247 Sec. 371 Date Jul. 22, 1996 Sec. 102(e) Date Jul. 22, 1996 PCT Filed May 13, 1994 PCT Pub. No. WO95/20195 PCT Pub. Date Jul. 27, 1995A mobile funds transaction device for transferring funds between one bank account or credit facility and another bank account or credit facility, the device having: a card reader device; a PINpad device with an encryption system; a modem device; a communication interface device connected with the modem device; an output report device; a wireless communication device; and a central processing device (CPU) to which are connected the above-listed devices. The CPU is programmed to store merchant identifying data of the owner/leasee of the device and to activate the PINpad device so a user can enter confidential identifying information to the CPU. The user then activates a communication connection via the modem device and the interface device to transmit the stored user entered data as well as transmit the merchant identifying data of the owner/leasee of the device, so that funds can be transferred from the user's bank account or credit or debit card to the owner/leasee's bank account or vice versa and to provide signals to the output report device confirming the transaction or other information relating to the transaction
Patent NZ-275620-A (NZ)
Title: 3-optionally substituted phenyl or naphthyl-1,2,4-triazole derivatives; pharmaceutical compositions
Inventor: DALTON CHRISTOPHER ROBIN
IPC: A61K31/41
Filed: 1994-10-04
Abstract: This invention relates to the enhancement of memory and cognition and the treatment of Alzheimer's disease and Wernicke-Korsakoff syndrome by administration of 3-aryl-4-alkyl and 4,5-dialkyl-4H-1,2,4-triazoles of formula (I) wherein R1 and R2 independently represent hydrogen, halogen, trifluoromethyl, nitro, C1-4 lower alkyl or C1-4 lower alkoxy, or together, R1 and R2 represent -CH=CH-CH=CH-, forming a 1- or 2-naphthylenyl ring system; R3 represents hydrogen or C1-4 lower alkyl; and R4 represents C1-4 lower alkyl, benzyl, or benzyl substituted by one or two groups selected from halogen, trifluoromethyl, nitro, C1-4 lower alkyl or C1-4 lower alkoxy.
Patent NZ-283075-A (NZ)
Title: Separating gas turbine engine airfoil to platform brazed connection by heating and pulling apart
Inventor: GOODWATER FRANK
IPC: B23P11/02
Filed: 1995-03-20
Abstract: A process and apparatus are provided for separating components of a brazed vane assembly by preheating the assembly to a temperature below the solidus of the base metal of the vane assembly and above the liquidus of the braze, then maintaining such temperature while separating the airfoil from the platform by pulling/pushing the airfoil and platform apart.
Patent NZ-312840-A (NZ)
Title: Ketoheterocyclic inhibitors of factor Xa
Inventor: MARLOWE CHARLES K
IPC: C07K5/072
Filed: 1996-06-05
Abstract: The present invention relates to ketoheterocyclic containing compounds of the formula 1 which are inhibitors of the isolated factor Xa which treats a condition in a mammal characterised by undesired thrombosis. Also claimed is a pharmaceutical composition caused by thrombosis, and a method for inhibiting the coagulation of biological samples.
Patent NZ-313016-A (NZ)
Title: Multi-level interconnect structure for switch and logic nodes
Inventor: REED COKE S
IPC: H04L12/56
Filed: 1996-07-19
Abstract: An interconnect apparatus includes a plurality of nodes and a plurality of interconnect lines selectively coupling the nodes in a multi-level structure.  The structure includes J+1 levels in a hierarchy of levels T arranged from a level T=0 to a level T=J as r increases, 2J-T rings in each level T, each ring being at a height z, and 2TK nodes in a ring spaced around the ring at position q.  A particular node A on a level T(T not being 0 or J) has an input from a node B on the T level, an input from a node C on level T+1, and outputs to nodes D and E on levels T and T-1 respectively.
Patent NZ-334885-A (NZ)
Title: Method for producing an igm preparation for intravenous administration
Inventor: RENTSCH MARKUS
IPC: A61K39/395
Filed: 1997-10-14
Abstract: A method of producing an intravenously administrable polyclonal, immunoglobulin preparation, that is not chemically modified, with an IgM proportion of more than 5% by weight, with respect to the total immunoglobulin proportion, and an anti-complementary activity of < 500 CH50/g protein comprising the steps of: (a) Selecting an IgM-containing plasma fraction; (b) Preparing an aqueous solution or suspension from the IgM-containing plasma fraction, the IgM proportion in the aqueous solution or suspension being more than 5% by weight; (c) Incubating the aqueous solution or suspension with a protease to reduce the anti-complementary activity of the aqueous solution or suspension to < 500 CH50/g protein.
Patent NZ-335835-A (NZ)
Title: Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
Inventor: WARREN KENNETH G
IPC: A61K31/17
Filed: 1999-05-17
Abstract: Human myelin basic protein (h-MBP) has a molecular weight of 18.5 KD and contains 170 amino acid residues. Synthetic peptides ranging in length from about 8 to 25 residues and covering the entire length of the protein have been produced. Antibodies to h-MBP (anti-MBP) were found to be neutralized by the synthetic peptides, in vitro, which span the h-MBP from about amino acid residue 61 to about amino acid residue 106. The peptides, which cover both the amino (about residues 1 to 63) and carboxy (about residues 117 to 162) terminals of h-MBP did not neutralize purified anti-MBP. Intrathecal administration of peptide MBP75-95, either as a single dose, or as repeated injections for periods up to 10 weeks, produced complete binding-neutralization of free (F) anti-MBP with no change in bound (B) levels. A control peptide MBP35-58 had no effect on F or B anti-MBP levels. Intravenous administration of MBP75-95 resulted in significant decline of F and B CSF anti-MBP levels over a period of one month. Administration of MBP synthetic peptides to MS patients either intrathecally or intravenously did not have any adverse neurological effects and systemic complications did not occur. The MBP epitope for MS anti-MBP has been localized to an area between Pro85 and Pro96.
Patent NZ-503239-A (NZ)
Title: Internet transaction processing interface for software applications residing in an object orientated client server environment
Inventor: SEGARAN CHENDRA
IPC: G06F17/00
Filed: 1998-08-12
Abstract: An Internet transaction process interface for software applications residing in an object oriented client server environment which dynamically generates HTML code. Internet user requests are passed from a web server to the object oriented environment. User session management, manages and maintains web connected users via use of TCP/IP address lists, unique session IDs and their corresponding session objects. Each session object calls upon pre-stored application forms which includes menus, controls and implicitly assigned data from the user requests. The controls are executed via a method and the output returned to the form, this is then converted to corresponding HTML strings and passed back to the web browser.
Patent NZ-503619-A (NZ)
Title: Fluorescent reporter molecules and their applications including assays for caspases
Inventor: WEBER ECKARD
IPC: G01N33/574
Filed: 1998-10-09
Abstract: A reporter compound of formula (I), (V), or a biologically acceptable salt or pro-reporter molecule where: R1 is an N-terminal protecting group; each AA independently is a residue of an a-amino acid or b-amino acid or a derivative of an a-amino acid or b-amino acid; each n is independently is 0-5; Y is a fluorogenic or fluorescent moiety; and for formula (V) R6 is a blocking group which is not an amino acid or a derivative of an amino acid. The compounds are fluorescent dyes used in the preparation of  fluorogenic  or florescent peptide or amino acid derivatives which are substrates of proteases  and peptidases, specifically substrates of enzymes involved in apoptosis such as caspases and the lymphocyte-derived serine protease Granzyme B.  A process is also provided for measuring the activity of caspases and other enzymes involved in apoptosis in living or dead whole cells, cell lines or tissue samples derived from healthy, diseased, infected or cancerous organ tissue.
Patent NZ-507619-A (NZ)
Title: Pharmaceutical aerosol formulation with liquefied propellant gas
Inventor: LLORCA NATHALIE
IPC: A61K47/06
Filed: 1999-04-15
Abstract: Pharmaceutical aerosol formulations comprising: (A) a therapeutic agent in the form of particles coated by at least one coating excipient and at least one surfactant, in suspension in (B) a liquefied propellant gas for the administration of therapeutic agents particularly by the pulmonary route and to a process for preparing these formulations.
Patent NZ-510993-A (NZ)
Title: Pharmaceutical formulation comprising omeprazole, a substituted pyridylsulfinylbenzimidazole a gastric acid secretion inhibitor, where the storage period is extended
Inventor: BERGSTRAND PONTUS
IPC: A61K9/36
Filed: 1999-11-03
Abstract: An enteric coated oral pharmaceutical formulation comprising as active ingredient a compound selected from the group of omeprazole, an alkaline salt of omeprazole, one of the single enantiomers of omeprazole and an alkaline salt of one of the single enantiomers of omeprazole, wherein the formulation comprises a core material that comprises the active ingredient and optionally an alkaline reacting compound.  The active ingredient is in admixture with a pharmaceutically acceptable excipient, such as a binding agent, and on the core material is a separating layer and an enteric coating layer.  A hydroxypropyl cellulose (HPC) with a specific cloud point is used in the manufacture of the claimed pharmaceutical formulations.  Furthermore, described is the process for their preparation and the use of the claimed formulations in medicine The figure shows two graphs representing two different dosage forms based on two qualities of HPC named Type A and Type B.  The graphs show released omeprazole from the dosage forms after 3 months and 6 months storage at accelerated conditions at 40oC and 75% relative humidity.  With a separating layer comprising HPC Type A the release rate of omeprazole over time has decreased.  With the HPC Type B the release rate of omeprazole over time is almost the same as for a freshly produced product.
Patent NZ-516721-A (NZ)
Title: Improved liquid smoke coloring agent solution made from liquid smoke organic precipitate
Inventor: MOELLER PATRICK W
IPC: A23L13/60
Filed: 2000-10-13
Abstract: A method for making a liquid smoke colouring agent solution comprising the step of contacting with water and an alkaline agent, a starting material liquid smoke composition having a benzo(a)pyrene content of under about 10 parts per billion and including an organic component that will fall out as an organic precipitate when the starting material liquid smoke composition is contacted with water. Producing from the organic precipitate a liquid smoke colouring agent solution that (a) has an alkaline pH above about 11, (b) is totally water miscible and (c) possesses a benzo(a)pyrene content less than about 5 parts per billion without treatment of the liquid smoke colouring agent solution for removal of benzo(a)pyrene.
Patent NZ-518385-A (NZ)
Title: Composition and methods for the control of plant growth
Inventor: SHAW DEREK RICHARD
IPC: B65D85/52
Filed: 2002-04-17
Abstract: A composition for use in a process for manufacturing a product for controlling plant growth, the composition including a water insoluble metallic salt, such as cuprous chloride, of between 20% and 40% by weight suitably compounded with a base polymer to form a plastic material such that when contacted with a suitable plant growing medium the ions of the metal salt are released to control the growth of plant roots.
Patent NZ-518635-A (NZ)
Title: Verbal classification system for the efficient sending and receiving of information
Inventor: WRENCH LISA MARIE
IPC: G06F17/30
Filed: 2000-10-31
Abstract: A verbal classification system and method for the efficient sending and receiving of desired information is described. Web-site proprietors (314) and Internet marketers provide a host server (320) with descriptive data about their web-sites and messages (336) according to a predefined verbal hierarchy of nouns, verbs and modifiers. An Internet user creates a role or roles (340) that describes desired information according to the same predefined verbal hierarchy of nouns, verbs, and modifiers and transmits that role (340) to the host server (320), provides the Internet user with desired web-site addresses (336) and message by matching the role (338) to web-site and message descriptive data (336). The Internet user may access a web-site using one or more roles (340) and the web- site may provide the user with custom content by matching content (338) to the Internet user's role and roles (340). The host server (320) collects role information (340) from Internet users and web-sites to generate marketing and demographics data (346) about Internet users and web-sites (328). Internet user privacy is protected because role data (340) is encrypted and contains no personal identification information (348).
Patent NZ-519715-A (NZ)
Title: High frequency inverter for electronic ballast or transformer
Inventor: HEIN PETER
IPC: H05K1/16
Filed: 2000-12-22
Abstract: An electronic ballast, includes a resonant load circuit (L1, C1) in series with a discharge lamp (LA), the resonant load circuit being supplied by an inverter (S1, S2) which outputs variable alternating voltages at frequencies above 200 KHZ. Alternatively, an electronic transformer incorporates a load circuit and a variable output frequency inverter for operating a low volt halogen lamp at variable alternating frequencies above 200 KHZ. Passive components of the ballast and transformer are integrated into a multilayer circuit.
Patent NZ-521289-A (NZ)
Title: Compounds for targeting
Inventor: EPENETOS AGAMEMNON ANTONIOU
IPC: C12N1/21
Filed: 2001-03-28
Abstract: Described is a compound comprising a target cell-specific portion and a cytotoxic portion, characterised in that the cytotoxic portion of the compound is a constitutively active caspase or has substantially the same apoptosis-inducing activity as the caspases. Further provided is a compound comprising a mediator portion and a cytotoxic portion, characterised in that the cytotoxic portion of the compound is a constitutively active caspase or has substantially the same apoptosis-inducing activity as the caspases. Preferably, the cytotoxic portion of the compounds disclosed is a constitutively active caspase-3, caspase-6 or caspase-7. Nucleic acids encoding the compounds their use in medicine, for the treatment of cancer, for example, is described also.
Patent NZ-524566-A (NZ)
Title: Dry-powder film coating composition and method of preparation
Inventor: GAYSER CHARLES W
IPC: A23L1/00
Filed: 2001-08-29
Abstract: A method of making a dry powder film forming composition capable of forming an aqueous solution having a low viscosity ranging from about 75 to about 150 cps and for use on pharmaceutical tablets, food and confectionary products, the method comprising the steps of mixing a dry powdered cellulosic polymer, a film forming amount of gum acacia, and a plasticizer in a blender until thoroughly dry mixed to form an edible film forming composition wherein said composition is no pre-wetted prior to being put into solution and used on said pharmaceutical tablets, food and confectionary products; and a dry powder film forming composition.
Patent NZ-527692-A (NZ)
Title: Cancer treatment
Inventor: LANE HEIDI
IPC: A61K33/243
Filed: 2002-02-18
Abstract: Use of rapamycin derivatives of formula (I) wherein, R1 is CH3 or C3-6alkynyl, R2 is H or -CH2-CH2-OH, and X is =O, (H,H) or (H,OH) provided that R2 is other than H when X is =O and R1 is CH3,in the preparation of a pharmaceutical composition for use in the treatment of solid tumors.
Patent NZ-529539-A (NZ)
Title: Secreted and transmembrane polypeptides and nucleic acids encoding the same
IPC: C12N15/63
Filed: 1999-12-01
Abstract: An isolated nucleic acid has at least 80% nucleic acid identity to a nucleotide sequence shown in Figure 3 (SEQ ID NO: 6), 80% nucleic acid identity to the DNA that encodes a polypeptide comprising the amino acid sequence shown in Figure 4 (SEQ ID NO:7) or has 80% nucleic acid identity to the DNA deposited under ATCC 203661. Also described are polypeptides, vectors, host, chimeric polypeptides and antibodies.
Patent NZ-533358-A (NZ)
Title: 3,4-Dihydro-1H-isoquinolin-2-yl-derivatives for use as NK2 receptor antagonists
Inventor: KEHLER JAN
IPC: A61P35/00
Filed: 2002-12-16
Abstract: Disclosed herein are 3,4-dihydro-1H-isoquinolin-2-yl-derivatives of formula (I) and a pharmaceutically acceptable acid addition salt thereof, wherein the variable groups are as defined in the specification, These compounds are suitable as neurokinin 2 (NK2) receptor antagonists and may be used for treating disorders of the central nervous system.
Patent NZ-533477-A (NZ)
Title: Water filter cartridge with means for activating inlet valve when cartridge is in place
Inventor: ROWE GREGORY NORMAN
IPC: B01D35/153
Filed: 2002-11-12
Abstract: A water filter which includes a cap 70 having an inlet 84 containing a valve 88, and an outlet is described. A housing 10 is fitted to the cap 70 and contains a removable filter cartridge 26. When the housing 10 is rotated in the bayonet fitting in order to connect to the cap 70, the filter cartridge 26 is also rotated, and a projection 56 at the upper end cap 40 of the filter cartridge 26 contacts the valve member 96 to open the valve. This means that the inlet valve 88 is only opened and flow through the filter water filter will only occur when a filter cartridge 26 is in place.
Patent NZ-533533-A (NZ)
Title: Deployment method and apparatus for moving stacked articles in varying orientations
Inventor: WILLIAMSON RHODERICK JOHN
Filed: 2004-06-11
Abstract: A deployment apparatus (1) adapted to remove articles (14) located on a support surface (5), the articles (14) being located in a plurality of orientations on the support surface (5). The deployment apparatus (1) includes; an article detector (2) capable of determining an orientation and position of at least one article located on the support surface (5), a removal system (4) capable of engaging with and removing an article (14) from the support surface (5), a manoeuvring system (3) capable of positioning the removal system (4) to engage with a selected article and deploying an engaged article to a predetermined position and/or orientation.
Patent NZ-536416-A (NZ)
Title: Production of crystalline materials by using high intensity ultrasound
Inventor: MCCAUSLAND LINDA JANE
IPC: B01D9/02
Filed: 2003-05-08
Abstract: A method for production of crystalline material comprises forming a saturated solution of the material, gradually changing the temperature of the solution so it becomes supersaturated, and subjecting the solution to irradiation by high intensity ultrasound. The temperature that provides the least degree of supersaturation at which crystals from the solution on brief application of ultrasound is found. The solution while it is supersaturated at this temperature is subjected to ultrasound for a brief interval of no more than 3 seconds such that crystals are formed. The crystals in the solution are then allowed to grow without irradiation by continuing to change the temperature of the solution.
Patent NZ-536668-A (NZ)
Title: An epithelial cell mucin MUC-1 antigen, which is capable of raising an immune response in vivo and is stable and has reduced susceptibility to recombination with respect to full-length MUC-1 (also known as episialin or polymorphic epithelial mucin, PEM)
Inventor: BURDEN NEIL
IPC: A61K35/76
Filed: 2003-05-23
Abstract: Described are nucleic acid constructs, useful in nucleic acid vaccination protocols for the treatment and prophylaxis of MUC-1 expressing tumours. In particular, the nucleic acid is DNA and the DNA constructs comprise a gene encoding a MUC-1 derivative having less than 10 perfect repeat units. Further provided are pharmaceutical compositions comprising the constructs, particularly pharmaceutical compositions adapted for particle mediated delivery, methods for producing them, and their use in medicine. The proteins encoded by the nucleic acids and pharmaceutical compositions containing them are also provided.